RU2672875C1 - Композиции PI3K/MTOR-ингибитора для внутривенного введения - Google Patents
Композиции PI3K/MTOR-ингибитора для внутривенного введения Download PDFInfo
- Publication number
- RU2672875C1 RU2672875C1 RU2017119282A RU2017119282A RU2672875C1 RU 2672875 C1 RU2672875 C1 RU 2672875C1 RU 2017119282 A RU2017119282 A RU 2017119282A RU 2017119282 A RU2017119282 A RU 2017119282A RU 2672875 C1 RU2672875 C1 RU 2672875C1
- Authority
- RU
- Russia
- Prior art keywords
- phenyl
- piperidin
- dimethylamino
- carbonyl
- urea
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462093060P | 2014-12-17 | 2014-12-17 | |
| US62/093,060 | 2014-12-17 | ||
| US201562250633P | 2015-11-04 | 2015-11-04 | |
| US62/250,633 | 2015-11-04 | ||
| PCT/IB2015/059515 WO2016097949A1 (en) | 2014-12-17 | 2015-12-10 | Formulations of a pi3k/mtor-inhibitor for intravenous administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2672875C1 true RU2672875C1 (ru) | 2018-11-20 |
Family
ID=54937330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017119282A RU2672875C1 (ru) | 2014-12-17 | 2015-12-10 | Композиции PI3K/MTOR-ингибитора для внутривенного введения |
Country Status (25)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3672571T (lt) | 2017-08-25 | 2021-12-10 | Pfizer Inc. | Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą |
| US12109308B2 (en) * | 2018-06-07 | 2024-10-08 | Pfizer Inc. | Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yljcarbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
| KR20240040768A (ko) | 2021-07-26 | 2024-03-28 | 셀퀴티 인크. | 암의 치료에 사용하기 위한 1-(4-{[4-(디메틸아미노)피페리딘-1-일]카르보닐}페닐)-3-[4-(4,6-디모르폴린-4-일-1,3,5-트리아진-2-일)페닐]우레아 (게다톨리십) 및 그의 조합물 |
| WO2025128712A1 (en) | 2023-12-12 | 2025-06-19 | Celcuity Inc. | Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea |
| US20260053814A1 (en) | 2024-08-21 | 2026-02-26 | Celcuity Inc. | Treatment regimens for gedatolisib in hormonally-driven disorders |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2509081C2 (ru) * | 2008-05-30 | 2014-03-10 | Дженентек, Инк. | Пуриновые соединения, ингибирующие рi3к, и способы применения |
| WO2014078522A1 (en) * | 2012-11-14 | 2014-05-22 | Ohio State Innovation Foundation | Materials and methods useful for treating glioblastoma |
| WO2014151853A1 (en) * | 2013-03-14 | 2014-09-25 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0852951A1 (de) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| AU2006251429A1 (en) * | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Combination therapy comprising a diaryl urea compound and a PI3, AKT kinase or mTOR inhibitors (rapamycins) for cancer treatment |
| US20080234262A1 (en) * | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| DE202008001253U1 (de) * | 2008-01-28 | 2008-04-10 | Mirror Image Ag | Bildanzeigegerät |
| MY155653A (en) | 2008-05-23 | 2015-11-13 | Wyeth Llc | Triazine compounds as p13 kinase and mtor inhibitors |
| WO2010096619A1 (en) * | 2009-02-23 | 2010-08-26 | Wyeth Llc | Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
| EP3116547B1 (en) * | 2014-03-14 | 2019-06-05 | Pfizer Inc | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
-
2015
- 2015-12-10 HU HUE15813578A patent/HUE055928T2/hu unknown
- 2015-12-10 PT PT158135780T patent/PT3233054T/pt unknown
- 2015-12-10 RS RS20211128A patent/RS62337B1/sr unknown
- 2015-12-10 HR HRP20211446TT patent/HRP20211446T1/hr unknown
- 2015-12-10 MX MX2017008072A patent/MX380172B/es unknown
- 2015-12-10 KR KR1020177016417A patent/KR102016822B1/ko active Active
- 2015-12-10 SG SG11201703826TA patent/SG11201703826TA/en unknown
- 2015-12-10 DK DK15813578.0T patent/DK3233054T3/da active
- 2015-12-10 NZ NZ731518A patent/NZ731518A/en unknown
- 2015-12-10 AU AU2015365497A patent/AU2015365497B2/en active Active
- 2015-12-10 PL PL15813578T patent/PL3233054T3/pl unknown
- 2015-12-10 SI SI201531687T patent/SI3233054T1/sl unknown
- 2015-12-10 RU RU2017119282A patent/RU2672875C1/ru active
- 2015-12-10 WO PCT/IB2015/059515 patent/WO2016097949A1/en not_active Ceased
- 2015-12-10 LT LTEPPCT/IB2015/059515T patent/LT3233054T/lt unknown
- 2015-12-10 CN CN201580068063.3A patent/CN107205923B/zh active Active
- 2015-12-10 EP EP15813578.0A patent/EP3233054B1/en active Active
- 2015-12-10 US US15/534,999 patent/US10172942B2/en active Active
- 2015-12-10 ES ES15813578T patent/ES2881214T3/es active Active
- 2015-12-14 TW TW104141933A patent/TWI660729B/zh active
- 2015-12-14 CA CA2915199A patent/CA2915199C/en active Active
- 2015-12-15 JP JP2015243831A patent/JP6420753B2/ja active Active
-
2017
- 2017-05-08 IL IL252158A patent/IL252158B/en active IP Right Grant
- 2017-06-01 ZA ZA201703764A patent/ZA201703764B/en unknown
-
2018
- 2018-11-13 US US16/189,009 patent/US10660959B2/en active Active
-
2021
- 2021-09-28 CY CY20211100851T patent/CY1124527T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2509081C2 (ru) * | 2008-05-30 | 2014-03-10 | Дженентек, Инк. | Пуриновые соединения, ингибирующие рi3к, и способы применения |
| WO2014078522A1 (en) * | 2012-11-14 | 2014-05-22 | Ohio State Innovation Foundation | Materials and methods useful for treating glioblastoma |
| WO2014151853A1 (en) * | 2013-03-14 | 2014-09-25 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
Non-Patent Citations (4)
| Title |
|---|
| Robert Mallon et al. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor // Clinical Cancer Research 17(10):3193-203. Aranapakam M. Venkatesan et al. Abstract 723: Beyond temsirolimus: Discovery of PKI-587 a highly efficacious dual PI3K/mTOR inhibitor // Cancer Research 70(8 Supplement):723-723. -2011. * |
| Robert Mallon et al. Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor // Clinical Cancer Research.- May 2011. -Volume 17, Issue 10. - P. 3193-3203. * |
| Venkatesan AM et al. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor // J Med Chem.- 2010. -25;53(6). -P. 2636-45. * |
| Venkatesan AM et al. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor // J Med Chem.- 2010. -25;53(6). -P. 2636-45. Robert Mallon et al. Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor // Clinical Cancer Research.- May 2011. -Volume 17, Issue 10. - P. 3193-3203. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10660959B2 (en) | Formulations of a PI3K/mTOR-inhibitor for intravenous administration | |
| US20230218628A1 (en) | Pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea | |
| AU2019321089A1 (en) | Liquid bendamustine pharmaceutical compositions | |
| ES2956225T3 (es) | Formulación acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]urea | |
| CN102772409B (zh) | 一种药物组合物 | |
| RU2772287C1 (ru) | Водный состав, содержащий 1-(4-{ [4-(диметиламино)пиперидин-1-ил]карбонил} фенил)-3-[4-(4,6-диморфолин-4-ил-1,3,5-триазин-2-ил)фенил]мочевину | |
| HK1241736A1 (en) | Formulations of a pi3k/mtor-inhibitor for intravenous administration | |
| HK1241736B (en) | Formulations of a pi3k/mtor-inhibitor for intravenous administration | |
| BR112017010841B1 (pt) | Formulações de um inibidor da pi3k/mtor para administração intravenosa |